When I made breakthroughs  in chemotherapy in 2008, I was so excited.  I was like I ran down the hall to my buddies in the ONC [Oncology Dept] world, and it's like, look at what just happened.  This is frickin crazy.  It's a vitamin A compound and look at what's frickin happening to the cancer cells.  Went back to my mentors, I was like, alright, breakthrough.  Now what?  And she's like, "Best case scenario will be 25 years before those guys down the hall are able to practice what you discovered.  25 years."  It turned out it would never come to be because as I moved into clinical trials, one of the pharmaceutical companies patented vitamin A compounds broadly as a chemotherapeutic agent.  So I called them up naively, very excited, got this thing working, doing this and that.  And it was literally three questions: 1) what type of cancers do you think it treats?  2) how long do you think you would have to treat for?  And 3) do you think it actually is getting out there, you know, at the apoptosis or suicide of the cell itself?  I said not only do I think, I can show you the data.  It was literally hung up me.  And I just thought the line went dead or lost my line.  I called back, no answer.   Finally, after a few days of no contact, I go to my mentor and explain the situation, and she's like, you should have never called.  That is not a patent.  That is there for monetary gain. That is something called a blocking patent, making sure that this thing doesn't come to light